CR9903A - Compuestos antihipercolesterolemicos - Google Patents

Compuestos antihipercolesterolemicos

Info

Publication number
CR9903A
CR9903A CR9903A CR9903A CR9903A CR 9903 A CR9903 A CR 9903A CR 9903 A CR9903 A CR 9903A CR 9903 A CR9903 A CR 9903A CR 9903 A CR9903 A CR 9903A
Authority
CR
Costa Rica
Prior art keywords
compounds
antihipercolesterolemicos
cholesterol
esters
absorption
Prior art date
Application number
CR9903A
Other languages
English (en)
Inventor
J Devita Robert
J Morrielo Gregori
Liin Peter
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CR9903A publication Critical patent/CR9903A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion proporciona inhibidores de la absorcion del colesterol de Formula I: y sales y esteres farmaceuticamente aceptables de los mismos. Los compuestos son utiles para disminuir los niveles de colesterol en plasma, particularmente colesterol LDL, y para tratar y prevenir la aterosclerosis y sucesos de enfermedad aterosclerotica.
CR9903A 2005-10-05 2008-04-18 Compuestos antihipercolesterolemicos CR9903A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72378105P 2005-10-05 2005-10-05

Publications (1)

Publication Number Publication Date
CR9903A true CR9903A (es) 2008-07-29

Family

ID=37845278

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9903A CR9903A (es) 2005-10-05 2008-04-18 Compuestos antihipercolesterolemicos

Country Status (25)

Country Link
US (2) US20090137546A1 (es)
EP (1) EP1934175B1 (es)
JP (1) JP4879991B2 (es)
KR (1) KR20080050610A (es)
CN (1) CN101277930A (es)
AR (1) AR058068A1 (es)
AT (1) ATE488495T1 (es)
AU (1) AU2006302584B2 (es)
BR (1) BRPI0616834A2 (es)
CA (1) CA2624481C (es)
CR (1) CR9903A (es)
DE (1) DE602006018341D1 (es)
DO (1) DOP2006000211A (es)
EA (1) EA200801008A1 (es)
ES (1) ES2354460T3 (es)
GT (1) GT200600444A (es)
IL (1) IL190434A0 (es)
MA (1) MA30006B1 (es)
NO (1) NO20082075L (es)
PE (1) PE20070493A1 (es)
SV (1) SV2009002863A (es)
TN (1) TNSN08153A1 (es)
TW (1) TW200806623A (es)
WO (1) WO2007044318A2 (es)
ZA (1) ZA200802587B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
ATE485267T1 (de) * 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057072A1 (es) * 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
TW200811098A (en) * 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
EP2124549A4 (en) * 2006-12-20 2010-01-20 Merck & Co Inc ANTIHYPERCHOLESTERINAMIC COMPOUNDS
DE102009023046B4 (de) 2008-05-30 2016-10-13 Hyundai Motor Company Automatisch schaltbares Getriebe eines Kraftfahrzeuges
WO2010056788A1 (en) * 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2525125B2 (ja) * 1991-07-23 1996-08-14 シェリング・コーポレーション 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
CA2191455A1 (en) * 1994-06-20 1995-12-28 Wayne Vaccaro Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
EP1345895B1 (de) * 2000-12-21 2006-12-27 Sanofi-Aventis Deutschland GmbH Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
CA2517571C (en) * 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
WO2006086562A2 (en) * 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
US7696177B2 (en) * 2005-06-15 2010-04-13 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2008052658A1 (de) * 2006-11-02 2008-05-08 Sanofi-Aventis Deutschland Gmbh Neues mit piperazin-1-sulfonsäure substituiertes diphenylazetidinon mit verbesserten pharmakologischen eigenschaften

Also Published As

Publication number Publication date
EP1934175A2 (en) 2008-06-25
IL190434A0 (en) 2008-11-03
WO2007044318A3 (en) 2007-07-12
AU2006302584A1 (en) 2007-04-19
EA200801008A1 (ru) 2009-02-27
BRPI0616834A2 (pt) 2016-08-23
KR20080050610A (ko) 2008-06-09
DOP2006000211A (es) 2007-05-31
AU2006302584B2 (en) 2011-10-13
ES2354460T3 (es) 2011-03-15
GT200600444A (es) 2007-05-04
TNSN08153A1 (en) 2009-10-30
SV2009002863A (es) 2009-02-19
US7704988B2 (en) 2010-04-27
CA2624481A1 (en) 2007-04-19
TW200806623A (en) 2008-02-01
ATE488495T1 (de) 2010-12-15
CA2624481C (en) 2012-04-03
JP4879991B2 (ja) 2012-02-22
CN101277930A (zh) 2008-10-01
DE602006018341D1 (de) 2010-12-30
US20070078098A1 (en) 2007-04-05
ZA200802587B (en) 2009-06-24
MA30006B1 (fr) 2008-12-01
US20090137546A1 (en) 2009-05-28
PE20070493A1 (es) 2007-06-13
AR058068A1 (es) 2008-01-23
JP2009511475A (ja) 2009-03-19
EP1934175B1 (en) 2010-11-17
NO20082075L (no) 2008-07-04
WO2007044318A2 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
CR9903A (es) Compuestos antihipercolesterolemicos
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
PA8680701A1 (es) Derivados de oxindol
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
ECSP078053A (es) Nuevos derivados de 2-azetidinona útiles en el tratamiento de condiciones de hiperlipidemia
WO2006138163A3 (en) Anti-hypercholesterolemic compounds
DOP2006000193A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
ECSP14002458A (es) Inhibidor de cetp de oxazolidona biciclico fusionado
WO2005062824A8 (en) Anti-hypercholesterolemic compounds
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
UY30627A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
GT200300054A (es) Compuestos que modulan la actividad de ppar
GT200300053A (es) Compuestos que modulan la actividad de ppar
UY30460A1 (es) Compuestos terapéuticos
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CR11272A (es) Enzimas de aciltranferasa de lecitina-colesterol, modificadas
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
CL2007002381A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis
PA8667201A1 (es) Nuevos compuestos farmaceuticos
EA200900073A1 (ru) КОМБИНАЦИЯ ИНГИБИТОРОВ HMG-CoA-РЕДУКТАЗЫ И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 4, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
ECSP056193A (es) Derivados sustituidos del pirrol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)